Fig. 2
From: Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer
Validation of circulating exosomal mRNAs (emRNAs) as novel biomarkers for PCa diagnosis. a, Heatmap demonstrates the significantly dysregulated emRNAs in PCa patients. Each column represents an individual sample, and each row represents an emRNA. b, Workflow of the validation of potential circulating emRNAs. c, The scatter plot shows that the expression levels of circulating emRNAs, including CDC42, IL32, MAX, NCF2, PDGFA and SRSF2, are upregulated in PCa patients (n = 141) compared to healthy controls (n = 30). d, The scatter plot shows that the expression levels of circulating emRNAs, including CDC42, IL32, MAX, NCF2, PDGFA and SRSF2, are upregulated in PCa patients (n = 141) compared to patients with BPH (negative prostate biopsy, n = 170). e and g, ROC analysis shows the diagnostic performance of 6 mRNAs and the emRNA-based screening model (CDC42, IL32, MAX, NCF2, PDGFA and SRSF2; AUC: 0.948; P < 0.0001). f and h, ROC analysis shows the diagnostic performance of 6 emRNAs and the emRNA-based diagnostic model (CDC42, IL32, MAX, NCF2, PDGFA and SRSF2) (AUC: 0.851; P < 0.0001)